Drug resistance of &lt;i&gt;M. tuberculosis&lt;/i&gt; (historical aspects, current level of knowledge)

Burmistrova, Irina A.; Samoilova, Anastasia; Тюлькова, Т. Е.; Ваниев, Э. В.; Баласанянц, Г. С.; Васильева, И. А.

doi:10.21292/2075-1230-2020-98-1-54-61

Cited by 10 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В последние годы в России заболеваемость и смертность населения от туберкулеза снижается [23], однако наблюдается рост частоты регистрации случаев заболевания, вызванного возбудителем с лекарственной устойчивостью [24]. В связи с этим постулат персонализированной медицины "лечить определенного пациента, определенное время и определенными лекарственными препаратами" становится все более актуальным.…”

Section: биобанкирование во фтизиатрииunclassified

Biobank as a key component of supporting research in phthisiology and infectious diseases

Umpeleva¹,

Vakhrusheva²,

Skornyakov³

2022

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Conducting fundamental and clinical research in the field of tuberculosis is an important step towards reducing related morbidity and mortality, but access to a sufficient number of high-quality samples required for research is an unsolved problem in Russia. This review is devoted to biobanking as a key component of modern research in personalized medicine, as well as to the status and prospects for developing this area in phthisiology and infectious diseases combined with tuberculosis.

show abstract

Section: биобанкирование во фтизиатрииunclassified

Biobank as a key component of supporting research in phthisiology and infectious diseases

Umpeleva¹,

Vakhrusheva²,

Skornyakov³

2022

Cardiovasc Ther Prev

View full text Add to dashboard Cite

show abstract

unclassified

“…Лекарственно-устойчивый туберкулез является глобальной проблемой здравоохранения, с которой столкнулось человечество в XXI в., как в России, так и во всем мире [1,13,15]. Туберкулез с лекарственной устойчивостью возбудителя (ЛУ) неотступно следует за антибактериальной терапией, приводя к недостаточной эффективности лечения, высокой смертности, большим экономическим затратам и снижению темпов улучшения эпидемиологических показателей [1,2,15]. Диагностика лекарственно-устойчивого туберкулеза во всем мире остается трудной задачей, так как требуются сложная лабораторная инфраструктура, адекватное кадровое обеспечение, внедрение быстрых методов обнаружения возбудителя и определения его ЛУ.…”

unclassified

“…Цель исследования: изучить распространенность и спектр мутаций в генах katG, inhA, ahpC, rpoB, ассоциированных с ЛУ Mycobacterium tuberculosis (МБТ) к изониазиду (H) и рифампицину (R), у больных с разными клиническими проявлениями туберкулеза легких. Многочисленными исследованиями было доказано, что ЛУ к изониазиду ассоциирована с мутациями ДНК M. tuberculosis в нескольких генах: katG, inhA, ahpC, кasA ndh, iniABC, fadE, furA, Rv1592c и Rv1772 [1,9,10,14], из которых основными являются мутации в трех генах: katG, inhA, ahpC [11]. Результаты обнаружения нами мутаций в генах katG, inhA, ahpС у больных 1-й группы и 2-й группы представлены в табл.…”

unclassified

See 1 more Smart Citation

Prevalence and Patterns of Gene Mutations Associated with <i>M. tuberculosis</i> Resistance to Isoniazid and Rifampicin in Patients with Different Clinical Manifestations of Tuberculosis

Салина

Morozova

2023

Tuberk. bolezni lëgk.

View full text Add to dashboard Cite

The objective: to study prevalence and patterns of mutations in the katG, inhA, ahpC, rpoB genes associated with Mycobacterium tuberculosis (MTB) resistance to isoniazid (H) and rifampicin (R) in patients with various clinical manifestations of pulmonary tuberculosis (TB).Subjects and Methods. 441 sputum samples collected in tuberculosis patients were tested using biological microchips. Tests were carried out in Group 1 - patients with confirmed bacterial excretion (n = 256) and in Group 2 (n = 185) - patients without bacterial excretion. The same patients were enrolled in Group 3 - patients with acute progressing tuberculosis (n = 52) and Group 4 (n = 99) - patients with localized tuberculosis.Results. In Group 1, DNA of Mycobacterium tuberculosis was found in 79.3% of patients, in Group 2 - in 57.8%. Among all samples, mutations in the genes encoding resistance to isoniazid were detected in 15.5%, resistance to rifampicin - in 58.1%. Resistance to isoniazid was more often caused by mutations in the katG gene (49%) versus the inhA (29%) and ahpC (4.2%) genes. We found 13 most common types of mutations in the rpoB gene associated with resistance to rifampicin. The dominant mutations in both groups were Seu531->Leu mutations - 19.7% in Group 1 and 24.3% in Group 2. In Group 1, mutations in the katG gene (53.7%) were observed more often than mutations in the inhA gene (27.7%). In Group 3, mutations in the katG gene were registered in 30.8%, in the inhA gene - in 25%. There were no statistically significant differences in patterns of mutations in the katG, inhA, ahpC, rpoB genes between Groups 1, 2 and 3, 4. Thus, patients without bacterial excretion and patients with localized tuberculosis are a hidden dangerous reservoir of tuberculous mycobacteria with multiple drug resistance to rifampicin and drug resistance to isoniazid.

show abstract

“…https://doi.org/10.26442/20751753.2021.9.200953 REVIEW Введение В России и во всем мире остается актуальной проблема лечения больных туберкулезом (ТБ) с множественной (МЛУ) и широкой лекарственной устойчивостью (ШЛУ), так как применяющиеся в настоящее время режимы химиотерапии традиционными противотуберкулезными препаратами недостаточно эффективны [1][2][3][4][5]. Кроме того, анализ результатов клинических исследований терапевтических схем, в том числе с использованием новых лекарственных средств, показывает высокую частоту нежелательных реакций [6][7][8][9].…”

unclassified

Mesenchymal stem cells in tuberculosis therapy

Remezova¹,

Gorelova²,

Muraviev³

et al. 2021

View full text Add to dashboard Cite

Tuberculosis, caused by the obligate intracellular microorganism Mycobacterium tuberculosis, is one of the oldest known infectious diseases in humans. Modern therapy of tuberculosis, consisting of several antibacterial drugs, is long-term, toxic and requires high compliance from the patient, therefore, the development of new therapeutic strategies that would minimize the duration of treatment and prevent the formation of drug-resistant forms of mycobacteria is relevant and important. Cellular therapy now holds the promise of potential complementary therapeutic options for the treatment of drug-resistant tuberculosis. In recent years, the possibilities of using mesenchymal stem cells in the treatment of tuberculosis of various localization have been widely studied. The use of such cells in conjunction with standard anti-tuberculosis therapy holds great promise for shortening the duration of treatment and reducing the formation of drug-resistant mycobacteria. This article describes the possibilities of using mesenchymal stem cells in the treatment of tuberculosis in patients, including those with extensive and multidrug resistance, as well as the mechanisms of interaction of mesenchymal stem cells with M. tuberculosis.

show abstract

Drug resistance of <i>M. tuberculosis</i> (historical aspects, current level of knowledge)

Cited by 10 publications

References 34 publications

Biobank as a key component of supporting research in phthisiology and infectious diseases

Biobank as a key component of supporting research in phthisiology and infectious diseases

Prevalence and Patterns of Gene Mutations Associated with <i>M. tuberculosis</i> Resistance to Isoniazid and Rifampicin in Patients with Different Clinical Manifestations of Tuberculosis

Mesenchymal stem cells in tuberculosis therapy

Contact Info

Product

Resources

About